Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema

被引:5
|
作者
Yozgat, Zubeyir [1 ]
Dogan, Mustafa [1 ]
Sabaner, Mehmet Cem [1 ]
Gobeka, Hamidu Hamisi [2 ]
Yazgan Akpolat, Serpil [3 ]
机构
[1] Afyonkarahisar Hlth Sci Univ, Afyon, Turkey
[2] Ibrahim Cecen Univ Agri, Agri Merkez, Turkey
[3] Malatya Inonu Univ, Malatya, Turkey
关键词
Aflibercept; Diabetic macular edema; Fundus fluorescein angiography; Microperimetry; Multifocal electroretinography; Optical coherence tomography;
D O I
10.1007/s10792-021-01737-w
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To evaluate anatomical and neuroretinal functional aspects in patients with diabetic macular edema (DME) after intravitreal anti-vascular endothelial growth factor (VEGF) therapy, in particular aflibercept. Materials and methods This prospective single-centered interventional study was performed at Afyonkarahisar Health Science University Faculty of Medicine, Department of Ophthalmology, where 32 eyes of 32 patients with DME were investigated. All patients received five intravitreal aflibercept injections on a monthly basis and were followed up for >= 6 months. After a comprehensive ophthalmological examination, including the measurements of visual acuity and intraocular pressure, and an antero-posterior segment slit-lamp biomicroscopy before and after full pupil dilation, fundus fluorescein angiography and optical coherence tomography were performed at baseline and during the third and sixth months post-therapy. Microperimetry and multifocal electroretinography were also performed at baseline and during the sixth months. Results Mean visual acuity increased from 0.73 to 0.57 and 0.33 logarithm of the minimum angle of resolution (logMAR) during the third and sixth months, respectively (p < 0.001). Changes in intraocular pressure were not statistically significant (p = 0.472). There was statistically significantly decreased mean central macular thickness from 390.2 mu m to 242.6 and 289.7 mu m during the third and sixth months, respectively (p < 0.001). Significantly improved fixation patterns during the sixth month, along with significantly increased macular sensitivity from 8.2 to 14.2 dB (p < 0.001) and significantly decreased local deficit from - 10.3 to 5.5 dB (p < 0.001) were observed. Further, there was a significantly increased N1 amplitude in the first ring and significantly increased P1 amplitude in all rings (p for each parameter < 0.05). There was also significantly decreased N1 wave implicit time in all rings and significantly decreased P1 wave in the second, third, fourth and fifth rings (p for each parameter < 0.05). Conclusions Patients with DME showed profound improvement in the retinal neurophysiological function, which was also accompanied by anatomical and ultrastructural integrity recovery after intravitreal aflibercept therapy. In the pathogenesis of DME, the influence of neurodegeneration has been increasingly gaining significant attention. Consequently, the need to assess neurophysiological effects of anti-VEGF therapy using a variety of diagnostic measures like electrophysiological studies and multimodal imaging technologies is undeniably growing.
引用
收藏
页码:1783 / 1798
页数:16
相关论文
共 50 条
  • [31] Intravitreal Anti-VEGF Therapy for Retinal Macroaneurysm
    Zweifel, S. A.
    Toenz, M. S.
    Pfenninger, L.
    Becker, M.
    Michels, S.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2013, 230 (04) : 392 - 395
  • [32] Baseline Outer Retinal Layer Thickness is Associated with Response of Diabetic Macular Edema to Anti-VEGF Therapy
    Mitzner, Margalit
    Fickweiler, Ward
    Robinson, Devon
    Boumenna, Tahani
    Aiello, Lloyd P.
    Sun, Jennifer K.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [33] Cost-effectiveness of intravitreal therapy with both anti-VEGF and Dexamethasone implant in patients with Diabetic Macular Edema
    Ricci, G. D'amico
    Bouzios, D.
    Boscia, F.
    Lupino, M.
    Pinna, A.
    ACTA OPHTHALMOLOGICA, 2017, 95
  • [34] Anti-VEGF therapies in diabetic retinopathy and diabetic macular edema
    Couzinet, Anne
    Mahieu, Laurence
    Pagot-Mathis, Veronique
    Mathis, Andre
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2009, 13 (04): : 155 - 159
  • [35] Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice
    del Cura Mar, Prieto
    Carballes, Maria J. C.
    Sastre-Ibanez, Marina
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2023, 71 (08) : 3091 - 3094
  • [36] The effect of anti-VEGF therapy on oxygen saturation and diameters of retinal vessels in patients with diabetic macular edema
    Ramm, Lisa
    Sandner, Dirk
    Burkert, Damian
    Stodtmeister, Richard P.
    Terai, Naim
    Pillunat, Lutz E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [37] ALTERATIONS IN VEGF, PEDF and PDGF LEVELS OF VITREOUS AND BLOOD IN RESPONSE TO INTRAVITREAL ANTI-VEGF THERAPY IN PATIENTS WITH DIABETIC MACULAR EDEMA
    Inan, Umit Ubeyt
    Polat, Onur
    Inan, Sibel
    Koken, Tulay
    Karadas, Mahmut
    Dogan, Mustafa
    Ucok, Kagan
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [38] Anti-VEGF agents in the management of diabetic macular edema
    Li, Angela S.
    Veerappan, Malini
    Mittal, Vaishali
    Do, Diana, V
    EXPERT REVIEW OF OPHTHALMOLOGY, 2020, 15 (05) : 285 - 295
  • [39] Anti-VEGF agents in the treatment of diabetic macular edema
    Konenkov, V. I.
    Klimontov, V. V.
    Chernykh, V. V.
    Tjan, N. V.
    DIABETES MELLITUS, 2013, 16 (04): : 78 - 84
  • [40] Evidence for Anti-VEGF Treatment of Diabetic Macular Edema
    Bandello, F.
    Berchicci, L.
    La Spina, C.
    Parodi, M. Battaglia
    Iacono, P.
    OPHTHALMIC RESEARCH, 2012, 48 : 16 - 20